|
HY-10095-10mg
|
MedChemexpress LLC
|
Olcegepant [CAS 204697-65-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095-2mg
|
MedChemexpress LLC
|
Olcegepant [CAS 204697-65-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095-25mg
|
MedChemexpress LLC
|
Olcegepant [CAS 204697-65-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095-5mg
|
MedChemexpress LLC
|
Olcegepant [CAS 204697-65-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095-50mg
|
MedChemexpress LLC
|
Olcegepant [CAS 204697-65-4]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095A-10mg
|
MedChemexpress LLC
|
Olcegepant (hydrochloride) [CAS 586368-06-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095A-100mg
|
MedChemexpress LLC
|
Olcegepant (hydrochloride) [CAS 586368-06-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095A-5mg
|
MedChemexpress LLC
|
Olcegepant (hydrochloride) [CAS 586368-06-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-10095A-50mg
|
MedChemexpress LLC
|
Olcegepant (hydrochloride) [CAS 586368-06-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-101283-10mg
|
MedChemexpress LLC
|
HCH6-1 [CAS 1435265-06-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-101283-100mg
|
MedChemexpress LLC
|
HCH6-1 [CAS 1435265-06-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-101283-5mg
|
MedChemexpress LLC
|
HCH6-1 [CAS 1435265-06-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-101283-50mg
|
MedChemexpress LLC
|
HCH6-1 [CAS 1435265-06-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-103080-1mg
|
MedChemexpress LLC
|
CMF019 [CAS 1586787-08-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-103080-10mg
|
MedChemexpress LLC
|
CMF019 [CAS 1586787-08-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-103080-5mg
|
MedChemexpress LLC
|
CMF019 [CAS 1586787-08-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-103286-10mg
|
MedChemexpress LLC
|
PD176252 [CAS 204067-01-6]
|
|
Cancer-programmed cell death
|
|
|
HY-103286-100mg
|
MedChemexpress LLC
|
PD176252 [CAS 204067-01-6]
|
|
Cancer-programmed cell death
|
|
|
HY-103286-25mg
|
MedChemexpress LLC
|
PD176252 [CAS 204067-01-6]
|
|
Cancer-programmed cell death
|
|
|
HY-103286-5mg
|
MedChemexpress LLC
|
PD176252 [CAS 204067-01-6]
|
|
Cancer-programmed cell death
|
|
|
HY-103286-50mg
|
MedChemexpress LLC
|
PD176252 [CAS 204067-01-6]
|
|
Cancer-programmed cell death
|
|
|
HY-103304-5mg
|
MedChemexpress LLC
|
CGRP antagonist 4 [CAS 217438-17-0]
|
|
|
|
|
HY-103546-1mg
|
MedChemexpress LLC
|
BETP [CAS 1371569-69-5]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-103546-10mg
|
MedChemexpress LLC
|
BETP [CAS 1371569-69-5]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-103546-100mg
|
MedChemexpress LLC
|
BETP [CAS 1371569-69-5]
|
|
Metabolism-sugar/lipid metabolism
|
|
